Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTRAP-Bleeding
NCT03801122Phase 2Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Mar 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tranexamic acid in hematological malignancy (3 arms), sponsored by CHU Saint-Etienne. Primary endpoint: Level of amplitude observed in thromboelastography at 30 days. Started Mar 2019; status: completed.
02
Drugs
tranexamic acid
03
Conditions
hematological malignancy
Beyond the preview
Go deeper on NCT03801122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801122.